Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, ...

Ali Eastburn missed her son’s rehearsal dinner — and nearly missed the wedding — when her appendix burst while traveling, ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.

Facebook posts reveal more GI side effects from semaglutide drugs like Ozempic than Mounjaro, offering new insights into ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...